ArticleTrials2025
A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundVitamin D deficiency is common in patients with end stage kidney disease (ESKD) and is a strong predictor of death from cardiovascular disease, infections and cancer. Currently only 68% of patients in the UK survive 3 years or more on dialysis. Vitamin D replacement typically utilises activated (1α-hydroxylated) vitamin D compounds allowing for impaired renal activation. However, this approach increases blood calcium concentrations and may paradoxically accelerate vitamin D catabolism. Contemporary treatment guidelines recommend replacement with inactive (unhydroxylated) vitamin D
methodsThe SIMPLIFIED (Survival Improvement with Cholecalciferol in Patients on Dialysis) trial will test whether supplementation with high-dose cholecalciferol improves survival. Adult dialysis patients will be recruited from one of 72 UK renal centres, by local clinicians and research nurses, and randomly assigned in a 1:1 ratio to high-dose open-label cholecalciferol or standard care, stratified by site. Trial outcomes will be captured using existing data sources including Office of National Statistics (ONS) for deaths and Hospital Episode Statistics (HES) for secondary endpoints. The primary endpoint of the trial is all-cause mortality. Key secondary endpoints include survival free from cardiovascular events, infections and cancers, and quality of life and cost-effectiveness measures utilising the Eq5D tool. Severe adverse event line listings will be generated from HES data for safety reporting. In this superiority trial, it is anticipated that approximately 4200 patients in total will need to be enrolled to observe 2200 deaths over a period of about 7 years, which will yield 90% power to demonstrate a hazard ratio of 0.87. DISCUSSION: Outcomes for patients on dialysis remain very poor. The pragmatic design of this study leveraging routinely collected data streamlines trial conduct, reducing burden on patients and local site study staff. Furthermore, since cholecalciferol is a low-cost and easy to administer intervention, evidence of benefit could be readily incorporated into dialysis care across healthcare systems globally.
trial registrationEudraCT Number: 2015-005003-88; ISRCTN Number: 15087616 (registration date 30th December 2015) ( https://doi.org/10.1186/ISRCTN15087616 ). Recruitment commenced in March 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.